{"id":2793,"date":"2021-05-18T09:53:56","date_gmt":"2021-05-18T07:53:56","guid":{"rendered":"https:\/\/www.hartwigmedicalfoundation.nl\/whole-genome-sequencing-voor-kankerdiagnostiek-klinisch-gevalideerd\/"},"modified":"2022-03-10T18:34:29","modified_gmt":"2022-03-10T17:34:29","slug":"whole-genome-sequencing-voor-kankerdiagnostiek-klinisch-gevalideerd","status":"publish","type":"post","link":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/whole-genome-sequencing-voor-kankerdiagnostiek-klinisch-gevalideerd\/","title":{"rendered":"Whole Genome Sequencing for cancer diagnostics clinically validated"},"content":{"rendered":"\n

Scientific research has demonstrated that Whole Genome Sequencing (WGS) is at least as reliable as routine diagnostic procedures. Clinical Molecular Biologist in Pathology Paul Roepman of Hartwig Medical Foundation in collaboration with national experts in the field recently published this research in<\/strong> The Journal of Molecular Diagnostics<\/strong><\/a>.<\/strong><\/p>\n\n\n\n

Measured reliably with a single WGS test<\/h2>\n\n\n\n

Together with academic partners Antoni van Leeuwenhoek \u2013 Netherlands Cancer Institute, Erasmus MC, Radboudumc, UMC Utrecht and Amsterdam UMC, they have shown that the results of WGS for detection of simple mutations, gene amplifications and deletions, and gene fusions are very similar to those of routine diagnostic procedures, with similarly high sensitivity. More complex tumor characteristics such as microsatellite instability (MSI), tumor mutational load and the presence of HPV can also be measured very reliably with a single WGS test. <\/p>\n\n\n\n

Independence of the research<\/h2>\n\n\n\n

As part of the validation of WGS for routine clinical use, results and outcomes were compared one-to-one with the findings of routine diagnostic tests. The academic partners helped to conduct the routine tests for this comparison to ensure the independence of the research. The researchers demonstrated the validity of the various results. For all types of abnormalities, the results of WGS when using frozen samples with sufficient tumor cells (20%) were at least equal to the results obtained with regular diagnostic tests.<\/p>\n\n\n\n

WIDE: prospective study to examine the utility of WGS in routine healthcare practice<\/h2>\n\n\n\n

This clinical validation is an important requirement for adopting new technology in routine healthcare. Meanwhile, researchers are also conducting a prospective study called WIDE to examine the utility of WGS in routine healthcare practice. WIDE stands for W<\/strong>GS I<\/strong>mplementation in standard D<\/strong>iagnostic tests for E<\/strong>very cancer patient. The interim analysis<\/a> of this study has been completed and confirms the clinical validity of WGS, but also revealed that WGS identifies more actionable biomarkers and thus provides additional treatment options for the patient.<\/p>\n\n\n\n

Further information<\/h2>\n\n\n\n